Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yes - the complex CNS indications are underrepresented in the EMA stats.

The stats you and others rely as representative of the Anavex chances in AD consist of a multitude of indications with an overweight of e.g. cancer, where risk/benefit is viewed with a very different perspective of eg. younger otherwise fully functional patients at risk of dying early.

One simply cannot take the topline conflated chance of EMA approval and transfer it to one specific indication and company like AD and Anavex.